Stryker (NYSE:SYK) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Stryker (NYSE:SYK) from a hold rating to a buy rating in a research note released on Sunday morning.

Other analysts have also issued research reports about the stock. Royal Bank Of Canada restated an “outperform” rating and issued a $435.00 target price on shares of Stryker in a research report on Friday, November 14th. Rothschild Redb raised Stryker to a “hold” rating in a report on Thursday, September 18th. Needham & Company LLC restated a “buy” rating and set a $448.00 price objective on shares of Stryker in a research report on Friday, November 14th. Evercore ISI dropped their target price on Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Finally, UBS Group set a $408.00 price target on Stryker in a research note on Monday, October 13th. Thirteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $431.84.

Stryker Stock Performance

NYSE:SYK opened at $355.21 on Friday. Stryker has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68. The stock’s 50-day simple moving average is $365.26 and its 200 day simple moving average is $377.45. The firm has a market capitalization of $135.84 billion, a PE ratio of 46.68, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter in the previous year, the firm earned $2.87 earnings per share. The business’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, analysts anticipate that Stryker will post 13.47 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be paid a $0.88 dividend. This is an increase from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, December 31st. Stryker’s payout ratio is presently 44.15%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the transaction, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the sale, the chief accounting officer directly owned 2,833 shares in the company, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 522,118 shares of company stock valued at $185,381,932. 5.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stryker

Institutional investors and hedge funds have recently made changes to their positions in the business. Mirabella Financial Services LLP lifted its stake in Stryker by 124.4% in the third quarter. Mirabella Financial Services LLP now owns 10,248 shares of the medical technology company’s stock valued at $3,781,000 after buying an additional 5,681 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of Stryker in the 3rd quarter valued at $55,000. Hudson Bay Capital Management LP boosted its stake in Stryker by 130.5% during the third quarter. Hudson Bay Capital Management LP now owns 568 shares of the medical technology company’s stock worth $210,000 after acquiring an additional 2,430 shares in the last quarter. Severin Investments LLC grew its holdings in Stryker by 24.1% in the third quarter. Severin Investments LLC now owns 1,499 shares of the medical technology company’s stock worth $554,000 after purchasing an additional 291 shares during the period. Finally, Swiss Life Asset Management Ltd increased its stake in Stryker by 7.0% in the third quarter. Swiss Life Asset Management Ltd now owns 37,984 shares of the medical technology company’s stock valued at $14,042,000 after purchasing an additional 2,486 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.